DrugPatentWatch Database Preview

Claims for Patent: 10,150,800

« Back to Dashboard

Summary for Patent: 10,150,800

Title:	EGFR-binding modular recognition domains
Abstract:	EGFR-binding modular recognition domains (MRDs) and complexes containing such MRDs linked to antibodies are described. The use of such MRDs and complexes are also described.
Inventor(s):	Roschke; Viktor (Bethesda, MD), Lafleur; David (Washington, DC), Hilbert; David M. (Bethesda, MD), Kiener; Peter (Potomac, MD)
Assignee:	Zyngenia, Inc. (Washington, DC)
Application Number:	14/776,816
Patent Claims:	1. A modular recognition domain (MRD) capable of binding an epidermal growth factor receptor (EGFR), wherein the MRD comprises the amino acid sequence YAEHCRQFPSDWICTLLP (SEQ ID NO: 3109). 2. A complex comprising the MRD of claim 1, wherein the MRD is fused to a heterologous protein. 3. The complex of claim 2, wherein the heterologous protein is an antibody. 4. The complex of claim 3, wherein the MRD and the antibody bind different targets. 5. The complex of claim 3, wherein the MRD and the antibody are operably linked by a linker. 6. The complex of claim 5, wherein the antibody binds EGFR. 7. The complex of claim 6, which further comprises an additional covalently bound MRD, wherein the additional covalently bound MRD binds Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3) and comprises an amino acid sequence selected from the group consisting of SEQ ID NO:3499-4094. 8. A pharmaceutical composition comprising the complex of claim 6. 9. The complex of claim 6, wherein the antibody is cetuximab. 10. The complex of claim 9, which further comprises an additional covalently bound MRD, wherein the additional covalently bound MRD binds ErbB3 and comprises an amino acid sequence selected from the group consisting of SEQ ID NO:3499-4094. 11. A pharmaceutical composition comprising the complex of claim 9. 12. A complex comprising an antibody and an MRD, wherein the antibody is cetuximab and the MRD comprises the amino acid sequence YAEHCRQFPSDWICTLLP (SEQ ID NO: 3109). 13. A pharmaceutical composition comprising the complex of claim 12.

Summary for Patent:   Start Trial

PCT Information
PCT Filed	March 14, 2014	PCT Application Number:	PCT/US2014/029077
PCT Publication Date:	September 18, 2014	PCT Publication Number:	WO2014/144600

Details for Patent 10,150,800

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Imclone	ERBITUX	cetuximab	VIAL; INTRAVENOUS	125084	001	2004-06-18		Zyngenia, Inc. (Washington, DC)	2039-02-26	RX	Orphan	search

International Patent Family for US Patent 10,150,800

Country	Patent Number	Estimated Expiration
South Africa	201507118
World Intellectual Property Organization (WIPO)	2014144600
United States of America	2016046678
Mexico	2015013163
Hong Kong	1222981
European Patent Office	2968541